Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
76.2M
-
Number of holders
-
36
-
Total shares
-
10.1M
-
Shares change
-
-433K
-
Total reported value, excl. options
-
$40.3M
-
Value change
-
-$3.24M
-
Number of buys
-
13
-
Number of sells
-
-17
-
Price
-
$4.00
Significant Holders of Xenon Pharmaceuticals Inc. - COMMON STOCK (XENE) as of Q1 2017
36 filings reported holding XENE - Xenon Pharmaceuticals Inc. - COMMON STOCK as of Q1 2017.
Xenon Pharmaceuticals Inc. - COMMON STOCK (XENE) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.1M shares
of 76.2M outstanding shares and own 13.22% of the company stock.
Largest 10 shareholders include BVF INC/IL (2.95M shares), Capital World Investors (1.43M shares), PERCEPTIVE ADVISORS LLC (724K shares), ORBIMED ADVISORS LLC (635K shares), Alyeska Investment Group, L.P. (440K shares), Invesco Private Capital, Inc. (381K shares), Opaleye Management Inc. (360K shares), Tekla Capital Management LLC (350K shares), Endurant Capital Management LP (341K shares), and DAFNA Capital Management LLC (340K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.